The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer. J Oncol Pharm Pract 2019 Apr;25(3):703-705
Date
12/30/2017Pubmed ID
29285995DOI
10.1177/1078155217748471Scopus ID
2-s2.0-85062584728 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Mycotic aneurysms are a fatal manifestation of disseminated fungal infections in immunocompromised hosts. We present a patient with an Aspergillus mycotic aneurysm after hematopoietic cell transplant. Due to CYP2C19 rapid metabolizer phenotype (*1/*17), therapeutic levels of voriconazole were unobtainable. Successful therapy was achieved with posaconazole salvage therapy and early, aggressive surgery. This case demonstrates the consequences of voriconazole rapid metabolism and the potential impact of genetic variants.
Author List
Wasko JA, Ustun C, Birkenbach M, Faizer R, Green JSMESH terms used to index this publication - Major topics in bold
Aneurysm, InfectedAntifungal Agents
Aspergillosis
Cytochrome P-450 CYP2C19
Hematopoietic Stem Cell Transplantation
Humans
Male
Middle Aged
Triazoles
Voriconazole